Premium
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis
Author(s) -
Chen Yuan,
Knösel Thomas,
Kristiansen Glen,
Pietas Agnieszka,
Garber Mitchell E,
Matsuhashi Sachiko,
Ozaki Iwata,
Petersen Iver
Publication year - 2003
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1378
Subject(s) - lung cancer , immunohistochemistry , adenocarcinoma , cancer research , biology , pathology , tissue microarray , western blot , cancer , lung , tumor suppressor gene , carcinoma , northern blot , carcinogenesis , complementary dna , medicine , gene , biochemistry , genetics
The programmed cell death 4 gene (PDCD4), a newly identified transformation suppressor, was analysed in lung tumour cell lines and primary lung carcinomas. Reduced PDCD4 mRNA expression was observed in two immortalized lung cell lines and 18 cancer cell lines by northern blot analysis. In the survey of primary lung tumours, PDCD4 cDNA was poorly represented in 47 lung tumours compared with normal lung tissue by cDNA microarray analysis and this poor representation was significantly associated with high‐grade (G3) adenocarcinomas ( p = 0.012). Immunohistochemical analysis of 124 primary carcinomas comprising all subtypes demonstrated that PDCD4 protein expression was widely lost in tumour samples (83%) and was negatively related to poor prognosis ( p = 0.013). The loss of PDCD4 expression correlated with higher grade and disease stage ( p = 0.045 and 0.034, respectively), but not tumour size and nodal status. Similarly to the cDNA data, lack of PDCD4 expression was significantly linked to tumour grade in adenocarcinoma ( n = 59, p = 0.048), while in squamous cell carcinoma ( n = 58), no relationship between PDCD4 expression and clinicopathological parameters was established. These data suggest that the loss of PDCD4 expression is a prognostic factor in lung cancer and may correlate with tumour progression. Copyright © 2003 John Wiley & Sons, Ltd.